HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis

Journal of Hepatology

Volumn 38, Issue 3, 2003, Pages 335-342

  Erhardt, Andreas ^a   Maschner Olberg, Andrea ^a   Mellenthin, Claudia ^a   Kappert, Günther ^b   Adams, Ortwin ^c   Donner, Andreas ^a   Willers, Reinhard ^d   Niederau, Claus ^a   Häussinger, Dieter ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Inst F Klin Chem L   (Germany)

^c Inst fur Med Mikrobiol Virologie   (Germany)

^d Inst für Med Statistik   (Germany)

Author keywords

Hemochromatosis; Hepatitis C virus; HFE

Indexed keywords

FERRITIN; IRON; TRANSFERRIN;

ADULT; ARTICLE; CALCULATION; CONTROLLED STUDY; FEMALE; FIBROSIS; GENE FREQUENCY; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HETEROZYGOSITY; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DETERMINATION; REGRESSION ANALYSIS; RISK; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STAINING; WILD TYPE;

EID: 0037336495     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(02)00415-4     Document Type: Article

References (36)

1. Hepatitis C: global prevalence. Wkly Epidemiol Rec 1997;72:341-4.
2. Niederau C, Erhardt A, Häussinger D, Strohmeyer G. Haemochromatosis and the liver. J Hepatol 1999;30(Suppl 1):6-11.
3. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-1262.
4. Arber N, Konikoff FM, Moshkowitz M, Baratz M, Hallak A, Santo M, et al. Increased serum iron and iron saturation without liver iron accumulation distinguish chronic hepatitis C from other chronic liver diseases. Dig Dis Sci 1994;39:2656-2659.
5. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-2113.
6. Piperno A, Sampietro M, D'Alba R, Roffi L, Fargion S, Parma S, et al. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996;16:248-254.
7. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997;25:759-768.
8. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
9. Edwards CQ, Griffen LM, Goldgar D, Drummond C, Skolnick MH, Kushner JP. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988;318:1355-1362.
10. Merryweather-Clarke AT, Pointon JJ, Shearman JD, Robson KJ. Global prevalence of putative haemochromatosis mutations. J Med Genet 1997;34:275-278.
11. Olynyk JK, Cullen DJ, Aquilia S, Rossi E, Summerville L, Powell LW. A population-based study of the clinical expression of the hemochromatosis gene. N Engl J Med 1999;341:718-724.
12. Hezode C, Cazeneuve C, Coue O, Roudot-Thoraval F, Lonjon I, Bastie A, et al. Liver iron accumulation in patients with chronic active hepatitis C: prevalence and role of hemochromatosis gene mutations and relationship with hepatic histological lesions. J Hepatol 1999;31:979-984.
13. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, Kaserer K, Hackl F, Polli C, et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999;116:127-134.
14. Beutler E. Genetic irony beyond haemochromatosis: clinical effects of HLA-H mutations. Lancet 1997;349:296-297.
15. Bonkovsky HL, Obando JV. Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis. Curr Gastroenterol Rep 1999;1:30-37.
16. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19:1321-1324.
17. Brunt EM. Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 2000;31:241-246.
18. Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991;13:372-374.
19. Powell LW, Nathan Subramaniam V, Yapp TR. Haemochromatosis in the new millenium. J Hepatol 2000;32(Suppl 1):48-62.
20. Adams PC, Kertesz AE, McLaren CE, Barr R, Bamford A, Chakrabarti S. Population screening for hemochromatosis: a comparison of unbound iron-binding capacity, transferrin saturation, and C282Y genotyping in 5,211 voluntary blood donors. Hepatology 2000;31:1160-1164.
21. Piperno A, Vergani A, Malosio I, Parma L, Fossati L, Ricci A, et al. Hepatic iron overload in patients with chronic viral hepatitis: role of HFE gene mutations. Hepatology 1998;28:1105-1109.
22. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000;32:135-138.
23. Farinati F, Cardin R, De Maria N, Della Libera G, Marafin C, Lecis E, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995;22:449-456.
24. Yano M, Hayashi H, Wakusawa S, Sanae F, Takikawa T, Shiono Y, et al. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 2002;97:133-137.
25. Fong TL, Han SH, Tsai NC, Morgan TR, Mizokami M, Qian D, et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol 1998;28:369-374.
26. Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology 2000;31:730-736.
27. Hezode C, Cazeneuve C, Coue O, Pawlotsky JM, Zafrani ES, Amselem S, et al. Hemochromatosis Cys282Tyr mutation and liver iron overload in patients with chronic active hepatitis C. Hepatology 1998;27:306.
28. Smith BC, Gorve J, Guzail MA, Day CP, Daly AK, Burt AD, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-1699.
29. Thorburn D, Curry G, Spooner R, Spence E, Oien K, Halls D, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002;50:248-252.
30. Pietrangelo A. Iron, oxidative stress and liver fibrogenesis. J Hepatol 1998;28(Suppl 1):8-13.
31. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 1997;349:825-832.
32. Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000;343:1529-1535.
33. Pirisi M, Toniutto P, Uzzau A, Fabris C, Avellini C, Scott C, et al. Carriage of HFE mutations and outcome of surgical resection for hepatocellular carcinoma in cirrhotic patients. Cancer 2000;89:297-302.
34. Niederau C, Fischer R, Purschel A, Stremmel W, Häussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-1119.
35. Pirisi M, Scott CA, Avellini C, Toniutto P, Fabris C, Soardo G, et al. Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations. Am J Clin Pathol 2000;113:546-554.
36. de Sousa M, Porto G. The immunological system in hemochromatosis. J Hepatol 1998;28(Suppl 1):1-7.